Related Experiment Video
Updated: May 28, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Oridonin Suppresses Colorectal Cancer Growth In Vitro and In Vivo: Evidence from Integrated Transcriptomic and
Menglong Xu1, Yongchao Li1, Wenqiang Sun1
1Department of Biochemistry and Molecular Biology, College of Life Science and Technology, the State Key Laboratory Incubation Base for Conservation and Utilization of Bio-Resource in the Tarim Basin of the Xinjiang Production and Construction Corps, Tarim University, Alar 843300, China.
Oridonin (ORI) effectively suppresses colorectal cancer (CRC) growth by regulating cell cycle progression and apoptosis. This natural compound shows promise as a potential therapeutic agent for advanced CRC.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Colorectal cancer (CRC) is a leading cause of cancer mortality with limited advanced treatment options.
- Oridonin (ORI), a natural diterpenoid, exhibits anti-tumor activity, but its mechanisms in CRC are not fully understood.
Purpose of the Study:
- To investigate the anti-cancer effects and molecular mechanisms of Oridonin (ORI) in colorectal cancer (CRC).
Main Methods:
- In vitro assays using HT-29 and HCT116 CRC cells.
- Integrated transcriptomic and proteomic analyses.
- Western blotting and HT-29 xenograft mouse model.
Main Results:
- ORI reduced CRC cell viability, induced G1 cell cycle arrest, and promoted cell death.
- Omics analyses revealed significant alterations in cell cycle regulation and apoptosis pathways.
- ORI modulated the expression of key apoptosis-related proteins (e.g., increased BAX, decreased BCL2) and inhibited tumor growth in vivo.
Conclusions:
- Oridonin (ORI) suppresses colorectal cancer (CRC) growth via coordinated regulation of cell cycle and apoptosis.
- ORI demonstrates potential as a therapeutic candidate for colorectal cancer (CRC).
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
06:24Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine
Published on: October 13, 2023
Related Concept Videos
Inhibition of Cdk Activity
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...